Clinical Study On The Long-term Efficacy Of Qingchang Wenzhongfang On Ulcerative Colitis In Remissio

Background:Ulcerative colitis is a non-specific inflammatory disease,mainly confined to the mucosa and submucosa,is a refractory disease.Its clinical symptoms are diarrhoea,purulent stool,abdominal pain and acute post-intestinal symptoms,such as arthritis,skin diseases and other extraintestinal manifestations,is a difficult-to-treat diseases of the digestive system.Traditional Chinese Medicine has obvious advantages in the treatment of UC.Professor Junxiang Li based on years of clinical experience in the treatment of UC,formulated Qingchang Wenzhong Decoction,a potent traditional Chinese herbal formulation.He believes that the reason why ulcerative colitis in remission is easy to recur is because the patient still has spleen deficiency,damp-heat and stasis in the body,so the patients in remission period should continue to take Qingchang Wenzhong Decoction,which has the function of invigorating spleen,clearing heat,dryness and dampness,activating blood circulation and removing blood stasis.Prevent and cure the recurrence of UC.Objective:To observe the safety of Qingchang Wenzhong Decoction and its effect on clinical symptoms,disease activity and quality of life of patients with ulcerative colitis in remission stage,and to provide scientific basis for its wide application in clinic.Methods:The subjects in this study came from Digestive outpatients of Dongfang hospital of Beijing University of Chinese Medicine,50 eligible patients with ulcerative colitis in remission were treated with Qingchang Wenzhong Decoction for 1 year.The whole course is treated with Qingchang Wenzhong Decoction,1 dose daily,2 times,1 hour after breakfast and dinner.During the medication,During the medication,patients should not eat milk,soybean milk,spicy,cold,crude fiber food(such as celery).They should avoid staying up late,tired,and avoid cold,anger.During the study,the patients were interviewed every 2 months,and the TCM syndrome scale and IBDQ scale were filled out.The patients were examined by enteroscopy at the end of the 12 months of treatment,and the safety tests were performed when the patients were included in the study and at the end of the 12 months of treatment.The data were analyzed by SPSS 17.0.Results:(1)General situation of patients:A total of 50 patients were enrolled in this study,7 of whom withdrew from the study and 43 patients completed the study.In terms of sex,32(64.0%)were male and 18(36.0%)were female.In terms of age,the youngest was 22 years old and the longest was 65 years old.The highest number of patients in 41-50-year-old group,accounting for 32.0%of the total,followed by 21-30-year-old group and 31-40-year-old group,12 patients in each group,accounting for 24.0%of the total number of patients.There were 8 patients in the 51-60-year-old group,accounting for 16%of the total and 2 cases in the 61-65-year-old age group,accounting for 4.0%of the total.Among the patients included,there were no patients in the 18-year-old 20-year-old group.In terms of course of disease,the number of patients reached a peak in 1-3-year group and 5-10-year group.1 patient with a course of disease less than 1 year,16 patients in 1-3-year group,9 patients in 3-5-year group,15 patients in 5-10-year group,9 patients with a course of more than 10 years.In terms of the range of pathological changes:rectal type patients accounted for the highest proportion.19 patients with rectal type,accounting for 38.0%of the total number of patients;17 patients with left semi-colon type,accounting for 34.0%of the total number of patients;14 patients with extensive colon type,accounting for 28%of the total number of patients.(2)General situation of recurrent patients:Sex:There are 6 male patients and 2 female patients.Age:In the 21-30-year-old group,the number of patients with recurrent disease was the highest,which was all male.There were 3 patients with recurrent disease in the 50-year-old age group,2patients were female.There was one male in the 51-60-year-old group.Course of disease:In this study,patients with 5-10 years of relapse accounted for 50%of the total number of relapse patients,occuping the main position.Extent of disease:There were 2 patients with rectal type relapsed,accounting for 25%of the total relapses.There were 4 patients with left semicolon type relapsed,accounting for 50%of the total relapses.There were 2 patients with extensive colon type recurred,accounting for 25%of the total relapse patients.(3)The curative effect of Qingchang Wenzhong DecoctionAfter 12 months of Qingchang Wenzhong Decoction treatment,the maintainable remission rate of UC patients in remission stage was 70%.Patients’ quality of life score in showed an overall upward trend in the aspects of intestinal symptoms,systemic symptoms,emotional ability,social ability and total score of IBDQ.Among them,systemic symptoms,emotional ability,social ability and total score of IBDQ were significantly higher than baseline(p<0.05 or p<0.01).Qingchang Wenzhong Decoction in the improvement of TCM syndromes,especially in loose stool,abdominal pain is significant,compared with the baseline,the difference is statistically significant(p<0.05 or p<0.01).Conclusions:Qingchang Wenzhong Decoction can effectively prevent the relapse of UC patients in remission stage.70%of patients remained in remission.Qingchang Wenzhong Decoction can effectively relieve the clinical symptoms,such as abdominal pain,loose stool,abdominal distension,less food,and improve the quality of life without obvious adverse reactions.